Search

En el Hospital Nacional Zacamil se realizó un estudio Descriptivo, retrospectivo de 44 casos de madres que tuvieron hijos con puntaje de APGAR bajo al primer o al quinto minuto de vida durante el año 2004, con el objetivo de conocer la frecuencia, factores obstétricos relacionados, vía del parto y métodos de reanimación utilizados en el neonato con APGAR bajo en el servicio de Partos de dicha institución. Se encontr6 que durante el año 2004 se asistieron un total de 3,027 partos de los cuales 44 casos tuvieron APGAR de 6 6 menos representando una frecuencia de 1.4%. De los neonatos con APGAR bajo al minuto se encontró una Casa de recuperación satisfactoria mayor al 80% a los 5min. La mayor incidencia se obsero6 en neonatos de termino con peso entre rangos normales. Se concluy6 que la edad materna, prirniparidad, control prenatal incompleto o ausente, distocias de parto y cesáreas son factores de riesgo para que el recién nacido presente APGAR bajo.

LY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort 1A) and at flat doses of 12.5 mg (cohort 1B) and 25 mg (cohort 2) over 3 h Q2W. Fourteen patients were enrolled in cohorts 1A (n = 2), 1B (n = 5), and 2 (n = 7). DLTs were experienced by both patients in cohort 1A (infusion-related reaction) and 2 patients in cohort 2 (cytokine release syndrome and infusion-related reaction). No MTD was determined. At the 25 mg dose level (cohort 2), after fifth infusion, LY3022859 had a short t1/2 (4.37-7.80 h) and rapid clearance (CLss, 0.412 L/h). Exposure increased twofold (from 28.5 to 60.2 μg·h/mL) with increase in dose from 12.5 to 25 mg. No accumulation was observed after repeat administration. The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines). clinicaltrials.gov Identifier: NCT01646203.